Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Methylnaltrexone Bromide Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects

NCT01366326
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Methylnaltrexone bromide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Not applicable Interventional Results available

Compassionate Use Study of Methylnaltrexone

NCT01368562
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Methylnaltrexone
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization

NCT01363323
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Methylnaltrexone (MNTX), Placebo, Moxifloxacin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
546 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 4 Interventional Results available

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

NCT00672477
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
29
States / cities
Mobile, Alabama • Laguna Hills, California • Lancaster, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 3 Interventional

Open-Label Treatment Extension of Protocol MNTX 302

NCT01367613
View directory record Official record
Conditions
Terminal Illness
Interventions
SC Methylnaltrexone
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 8, 2026, 11:50 AM EDT
Withdrawn Phase 3 Interventional

Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates

NCT01360372
View directory record Official record
Conditions
Tube Feeding
Interventions
Methylnaltrexone, Saline injection
Drug
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 8, 2026, 11:50 AM EDT
Terminated Phase 4 Interventional Results available

Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

NCT02977286
View directory record Official record
Conditions
Constipation
Interventions
Naloxegol Oral Tablet, Placebo Oral Tablet, Docusate Sodium 100 Mg oral capsule [Colace], Senna 217 Mg Oral Tablet, Polyethylene Glycols, Bisacodyl 10 mg Suppository, Magnesium Citrate Oral Liquid Product, Methylnaltrexone
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 8, 2026, 11:50 AM EDT
Withdrawn Phase 2Phase 3 Interventional

A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

NCT04083651
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Methylnaltrexone bromide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Sep 8, 2026, 11:50 AM EDT
Recruiting Phase 4 Interventional

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

NCT06162377
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Methylnaltrexone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function

NCT01367561
View directory record Official record
Conditions
Healthy Males
Interventions
Naloxone, IV Methylnaltrexone (MNTX), Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX

NCT01367483
View directory record Official record
Conditions
Healthy Male Volunteers
Interventions
IV methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 4 Interventional

Methylnaltrexone Use for Opioid-induced Postoperative Constipation

NCT01773096
View directory record Official record
Conditions
Constipation
Interventions
Methylnaltrexone, Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax
Drug
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
12 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)

NCT00401375
View directory record Official record
Conditions
Post-Operative Ileus (POI)
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide

NCT01366365
View directory record Official record
Conditions
Healthy Adults
Interventions
methylnaltrexone, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

NCT00528970
View directory record Official record
Conditions
Ileus
Interventions
MOA-728, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
75
States / cities
Benton, Arkansas • Colton, California • Laguna Hills, California + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function

NCT01367509
View directory record Official record
Conditions
Renal Impairment
Interventions
Methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 3 Interventional

Study of Methylnaltrexone (MNTX) for the Relief of Constipation

NCT00402038
View directory record Official record
Conditions
Advance Illness Patients With OIC
Interventions
SC Methylnaltrexone, SC Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 4 Interventional Results available

Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine

NCT02403830
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Methylnaltrexone, Placebo, Morphine, Ticagrelor
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

NCT00529087
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728), placebo
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Mobile, Alabama • Sun City, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

NCT00547586
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728), placebo
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Mobile, Alabama • Litchfield Park, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tolerance and Pharmacokinetics Study of MNTX Tablets

NCT01366339
View directory record Official record
Conditions
Normal Healthy Volunteers
Interventions
Oral methylnaltrexone, Oral placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 8, 2026, 11:50 AM EDT
Withdrawn Phase 4 Interventional

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

NCT00858754
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
methylnaltrexone, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Laguna Hills, California • Lancaster, California • Flat Rock, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

NCT01004393
View directory record Official record
Conditions
Neoplasms, Constipation, Opioid-Related Disorders
Interventions
Methylnaltrexone bromide
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Sep 8, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

NCT00804141
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
94
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Sep 8, 2026, 11:50 AM EDT